Prescriptions Without the Markup

Gerald Pruitt is 71, a retired ironworker from Gary, Indiana, and he takes two medications. Rosuvastatin for cholesterol and empagliflozin for his kidneys, prescribed after a scare three years ago that put him in the hospital for four days. Together they cost $1,100 a month at his local Walgreens. His Medicare Part D plan covers neither at a price he can absorb. The rosuvastatin copay is $74. The empagliflozin, a branded drug with no generic equivalent, is $1,026.

Gerald asked his pharmacist if there was anything she could do. She is a good pharmacist. She told him no, because within the system she operates in, the answer is no. Her dispensing software prices the drug according to the contract between her pharmacy and its pharmacy benefit manager, and that contract does not include a mechanism for her to find Gerald a lower price. She is not hiding anything from him. She is inside a system that hides things from both of them.

On a Saturday afternoon, Gerald’s daughter Keisha ran his two prescriptions through a buying agent she had been reading about. The agent found rosuvastatin through Mark Cuban’s Cost Plus Drug Company for $8 a month, a transparent 15% markup over the manufacturer’s cost for a generic that Walgreens was dispensing at nine times that price. It found empagliflozin for $0 through the manufacturer’s patient assistance program, which Gerald qualifies for based on his income. His new monthly total: $8. The $1,092 difference was not a discount. It was the distance between what the system charged him and what the medication actually costs when someone is looking out for him instead of billing him.

How American Pharmacy Pricing Works

#

The price Gerald pays at Walgreens is not set by Walgreens. It is set by a pharmacy benefit manager, a company most patients have never heard of. Three PBMs control roughly 80% of the American prescription drug market: CVS Caremark, Express Scripts, and OptumRx. They negotiate drug prices with manufacturers, set reimbursement rates for pharmacies, manage the formulary that determines which drugs your insurance covers, and collect rebates from manufacturers that are not passed through to patients. The entire process happens behind contracts that are legally protected from public disclosure.

The result is a pricing system where the same drug, at the same dose, in the same city, can cost $14 at one pharmacy and $380 at another. The difference is not quality. It is contracts. Gerald’s Walgreens has one contract with one PBM. The independent pharmacy four miles away has a different contract with a different PBM. The prices they charge Gerald for the same molecule reflect their respective contractual positions, not his clinical need or the drug’s manufacturing cost.

Spread pricing is the specific mechanism. The PBM charges Gerald’s insurance plan one price for the drug and reimburses the pharmacy a lower price. The PBM keeps the difference. DIR fees, which stands for direct and indirect remuneration, are additional clawbacks the PBM applies to the pharmacy after the transaction, sometimes months later, reducing the pharmacy’s effective reimbursement further. The pharmacy raises its cash prices to compensate. Gerald pays more. The pharmacist makes less. The PBM collects from both sides.

None of this is illegal. The opacity is the product.

GoodRx: Real Savings, Real Tradeoff

#

Gerald’s neighbor Maxine uses GoodRx and has for three years. It saves her $40 a month on her blood pressure medication, and those savings are genuine. GoodRx negotiates discount rates with pharmacies and presents them to consumers through its app, often producing prices 30% to 80% below what the pharmacy charges without a coupon.

What Maxine does not know, because it is disclosed in the terms of service she did not read, is that GoodRx sells her prescription data to pharmaceutical manufacturers and pharmacy benefit managers. Her medication history, dosage changes, prescription frequency, and the pharmacy she uses are commercially available data. In 2023, GoodRx settled with the FTC for $1.5 million over unauthorized sharing of health data with advertising platforms including Facebook and Google. The savings are real. The privacy cost is real. The disclosure of the privacy cost is technically present and practically invisible.

A buying agent can use GoodRx’s pricing data as one comparison point without requiring Gerald to create an account, share his prescription data, or agree to terms he has not read. The agent accesses the price. Gerald does not become the product.

Cost Plus: What It Does and What It Doesn’t

#

Cost Plus Drug Company operates on a simple model: manufacturer’s cost plus a flat 15% markup plus a $5 pharmacy fee plus $5 shipping. The price for every drug in its formulary is published on its website, and the math is visible. Gerald’s rosuvastatin at Cost Plus: $3 manufacturer cost, $0.45 markup, $5 dispensing fee, $5 shipping. Total: $13.45 for a 90-day supply. Monthly: roughly $4.50. Even rounding up to $8 for the monthly comparison, it is a fraction of what he was paying.

The limitation is the formulary. Cost Plus carries primarily generics, with a growing but still limited selection of branded medications. For Gerald’s rosuvastatin, a widely available generic statin, Cost Plus is the obvious choice. For his empagliflozin, a branded medication still under patent protection from its manufacturer, Cost Plus does not carry it and cannot offer a competitive price. The model works where generics exist. Where they do not, the agent looks elsewhere.

Patient Assistance Programs

#

Empagliflozin is manufactured by Boehringer Ingelheim. Boehringer Ingelheim operates a patient assistance program called Boehringer Cares that provides the drug free to patients who meet income requirements. Gerald, with his Social Security and ironworker pension totaling $2,400 a month, qualifies.

He did not know the program existed. His pharmacist did not mention it because pharmacy staff are not trained to navigate manufacturer assistance programs and the software they use does not surface them. His doctor’s office did not mention it because physician practices are not reimbursed for the administrative time required to identify and apply for patient assistance, and the time is substantial. The databases that catalog these programs, NeedyMeds, RxAssist, the NCOA BenefitsCheckUp tool, are free to search. But searching them requires knowing they exist, knowing that your specific drug has a program, completing a multi-part application that requires a physician’s signature, and following up to confirm enrollment. The process is not simple by accident. It is complex because the manufacturer benefits from low enrollment.

The buying agent found the program, confirmed Gerald’s eligibility based on his income data, pre-filled the application, and routed the physician signature request through an electronic portal Gerald’s doctor’s office already uses for prior authorizations. Eleven days from identification to enrollment. Gerald now pays $0 for the drug that was costing him $1,026 a month.

Patient assistance programs are not new. They have existed for decades. The National Council on Aging estimates that millions of Medicare beneficiaries who qualify for pharmaceutical assistance programs never apply. The programs are a genuine resource wrapped in an administrative process designed to limit the number of people who successfully use them. The agent does not change the program. It changes how many people get through the door.

Canadian Pharmacies

#

For medications where no domestic alternative produces an affordable price and no patient assistance program exists, Canadian pharmacies are a legal option for personal importation in most circumstances. The FDA has historically exercised enforcement discretion for personal imports of 90-day supplies from licensed Canadian pharmacies. CIPA certification, issued by the Canadian International Pharmacy Association, is the primary verification mechanism for identifying legitimate operations.

Gerald did not need this option. His two medications were covered by Cost Plus and the manufacturer’s program. But many readers of this article will need it for medications where neither alternative applies, particularly branded drugs with no patient assistance program or drugs in therapeutic categories where U.S. pricing is five to ten times the Canadian price for the same product from the same manufacturer. A buying agent that includes CIPA-certified Canadian pharmacy pricing in its comparison set gives the user access to a legal alternative most Americans do not know is available.

The process is not instant. Orders typically take two to four weeks. The pharmacy requires a valid U.S. prescription. The savings on branded medications can be 50% to 80% of the U.S. retail price. It is worth understanding for the specific situations where domestic options have been exhausted.

The Information Was Always There

#

Everything that saved Gerald money was publicly available before his daughter found the buying agent. Cost Plus publishes its prices. NeedyMeds publishes its database. CIPA publishes its list of certified pharmacies. GoodRx publishes its coupons. The information existed. What did not exist was someone assembling it on Gerald’s behalf, checking his eligibility, completing the applications, and presenting the results in a form he could act on during a Saturday afternoon.

People with resources have always had this. The retired executive with a concierge physician gets patient assistance applications handled by the practice’s administrative staff. The upper-middle-class family with a pharmacist relative gets tipped off about Cost Plus. The information advantage is not new. The distribution of that advantage is what is changing.

The change is partial. Gerald needed a daughter who researches things and a smartphone in her hand. His neighbor down the street, 78, lives alone, does not use a smartphone, and pays full price for four medications she probably qualifies for assistance on. The agent does not reach her yet. Partial is the honest ceiling, and it sits next to the $1,092 that Gerald is no longer paying.

What It Cannot Do

#

The agent cannot evaluate whether Gerald’s pharmacist relationship is worth a price premium. His Walgreens pharmacist has caught a drug interaction that a mail-order pharmacy would not have caught, two years ago, on a Tuesday afternoon when Gerald came in with a new prescription from an urgent care clinic that did not have his full medication history. That catch may have prevented a hospitalization. No buying agent would have flagged it. No algorithm would have noticed the handwriting on the urgent care prescription and recognized the conflict with the metoprolol Gerald had been taking for six years.

The agent also cannot assess medication quality at the level a pharmacist can. It found the cheapest accredited source. It did not evaluate the supplier’s storage conditions, the pharmacy’s dispensing accuracy record, or the customer service experience Gerald would have when the shipment was delayed by two days and he needed to know whether to skip a dose or split a remaining tablet. These are judgment calls that require a human who knows Gerald, and the agent is not that human.

Gerald uses the agent for his rosuvastatin and the patient assistance program for his empagliflozin. He still fills his blood pressure medication at Walgreens because he trusts his pharmacist and the $12 monthly premium over Cost Plus is worth what that trust provides. The agent did not tell him to leave Walgreens. It told him where Walgreens was the right choice and where it was not, and it let him decide.